¿©¼º °Ç°­¿¡¼­ ÆèÅ×Å©¿Í ¸ÂÃãÇü ÀÇ·áÀÇ À¶ÇÕ
»óǰÄÚµå : 1812611
¸®¼­Ä¡»ç : FirstWord Group
¹ßÇàÀÏ : 2025³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 8,000 £Ü 11,384,000
Multi User License (PDF) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. PDF ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

º» º¸°í¼­´Â ÆèÅ×Å©¿Í ¸ÂÃãÇü ÀÇ·áÀÇ ±³Â÷Á¡À» »ìÆìº¸°í, µðÁöÅÐ Çコ Çõ½ÅÀÌ ¿©¼º °Ç°­ÀÇ »óȲÀ» ¾î¶»°Ô À籸¼ºÇϰí ÀÖ´ÂÁö¸¦ ºÐ¼®ÇÕ´Ï´Ù. ¼ÒºñÀÚ Áß½ÉÀÇ ¾ÖÇø®ÄÉÀ̼ǿ¡¼­ ÀÓ»óÀûÀ¸·Î ÅëÇÕµÈ ¼Ö·ç¼ÇÀ¸·Î ÁøÈ­ÇÏ´Â ÆèÅ×Å©ÀÇ ÁøÈ­, ¿©¼º °Ç°­ ¿¬±¸ÀÇ Áö¼ÓÀûÀÎ µ¥ÀÌÅÍ °ÝÂ÷, źźÇÑ ½ÇÁ¦ Áõ°Å¸¦ »ý¼ºÇϱâ À§ÇÑ °úÁ¦¸¦ ޱ¸Çϰí ÀÖ½À´Ï´Ù.

µðÁöÅÐ ±â¼úÀ» ±âÁ¸ ÀǾàǰ Ä¡·á¿Í ÅëÇÕÇÏ´Â Àü·«, Á¾ÇÕÀûÀÎ ÀÓ»ó½ÃÇè ¼³°èÀÇ Á߿伺, Á¦¾àȸ»ç¿Í ÆèÅ×Å© ½ºÅ¸Æ®¾÷ °£ÀÇ ÆÄÆ®³Ê½ÊÀÇ Áß¿äÇÑ ¿ªÇÒ¿¡ ´ëÇÑ ÀλçÀÌÆ®¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. ÀÌ º¸°í¼­´Â ¶ÇÇÑ Çõ½ÅÀ» ÃËÁøÇÏ´Â µ¥ ÇÊ¿äÇÑ »ó¾÷Àû ¹× ±ÔÁ¦Àû °í·Á»çÇ×À» ´Ù·ç°í, Çù·ÂÀûÀÌ°í µ¥ÀÌÅÍ ±â¹Ý Á¢±Ù ¹æ½ÄÀ» ÅëÇØ ¿©¼ºÀÇ °Ç°­ °á°ú¸¦ °³¼±ÇÔÀ¸·Î½á ¾òÀ» ¼ö ÀÖ´Â ±¤¹üÀ§ÇÑ °æÁ¦Àû, »çȸÀû ¿µÇâÀ» °­Á¶ÇÕ´Ï´Ù.

´äº¯µÈ ÁÖ¿ä Áú¹®

ÁÖ¿ä ±â¾÷

  • Clue
  • Evinova
  • IBSA UK
  • Theramex
  • UCB
  • QVin
  • Genentech
  • K'ept Health
  • TherapeuticsMD
  • Agile
  • Eli Health
  • Noom
  • Wisp
  • Incora Health
  • Aura Fertility
  • LiGalli Health
  • Novartis
  • ImageBiopsy Lab
  • Organon
  • Boston Consulting Group

Âü¿© Àü¹®°¡ ÀϺΠ¸ñ·Ï

Á¶»ç ¹æ¹ý

µµ½Ã¿¡ º¸°í¼­´Â µ¶ÀÚÀûÀÎ ¾÷°è Á¶»ç¿Í ¾÷°è ¿ÀÇǴϾ𠸮´õµé°úÀÇ ½ÉÃþ ÀÎÅͺ並 ÅëÇØ ¾òÀº µ¶¸³ÀûÀÌ°í °£°áÇÑ ºÐ¼®À» ¹ÙÅÁÀ¸·Î °³¹ßµÇ¾ú½À´Ï´Ù. ÀÌ º¸°í¼­´Â Á¦¾à ±â¾÷ °æ¿µÁøÀÌ ¾ÕÀ¸·Î ´Ù°¡¿Ã ±âȸ¿Í µµÀüÀ» °ü¸®Çϱâ À§ÇØ ÀÌÇØÇØ¾ß ÇÒ Áß¿äÇÑ ¹ßÀü°ú ½ÃÀå µ¿ÇâÀ» »ó¼¼È÷ ºÐ¼®ÇÕ´Ï´Ù. °¢ º¸°í¼­ÀÇ ÃÊÁ¡Àº 2Â÷ ¹®Çå °ËÅä¿Í È®ÀÎµÈ Áö½Ä °ÝÂ÷¿¡ µû¶ó Á¤Àǵ˴ϴÙ. ÀÌ Ãʱâ Á¶»ç¸¦ ¹ÙÅÁÀ¸·Î Áõ°Å¿¡ ±â¹ÝÇϰí Àü¹®°¡ÀÇ ÀǰßÀ» ¹Ý¿µÇÑ Åä·Ð °¡À̵带 ÀÛ¼ºÇÏ¿© °¡Àå Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äÀ» ¾òÀ» ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. ¶ÇÇÑ, ÀÎÅÍºä ´ë»óÀÚ°¡ ÇØ´ç ÁÖÁ¦¿¡ ´ëÇØ À̾߱âÇϱ⿡ ÀûÇÕÇÑ °æÇè, Áö½Ä, ÁöÀ§¸¦ °®Ãß°í ÀÖ´ÂÁö È®ÀÎÇϱâ À§ÇØ ¾ö°ÝÇÑ ½É»ç ±âÁØÀ» ¸¶·ÃÇϰí ÀÖ½À´Ï´Ù.

´ç»ç º¸°í¼­ÀÇ Æ¯Â¡

FirstWord Reports´Â Á¦¾à ºÎ¹®¿¡ ƯȭµÈ ½Å·ÚÇÒ ¼ö ÀÖ´Â ¾÷°è ¸®´õ·Î¼­ ¹ÙÀÌ¿À Á¦¾à Àü¹®°¡¿Í ÀÇ»ç°áÁ¤±ÇÀÚ¸¦ À§ÇÑ »ó¼¼ÇÏ°í ½Ç¿ëÀûÀÎ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù. ´ç»çÀÇ ½ÉÃþÀûÀÎ ¾÷°è Áö½ÄÀº °í°´ÀÌ »õ·Î¿î Æ®·»µå¸¦ ÆÄ¾ÇÇÏ°í º¹ÀâÇÑ ¹®Á¦¸¦ È¿°úÀûÀ¸·Î ÇØ°áÇÒ ¼ö ÀÖµµ·Ï ÀûÀýÇÏ°í °¡Ä¡ ÀÖ´Â ÀλçÀÌÆ®¸¦ Á¦°øÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù. ±¤¹üÀ§ÇÑ Á¶»ç¿Í ÃÖ°í ¼öÁØÀÇ Àü¹®°¡ ¹× KOLÀÇ µ¶¸³ÀûÀÌ°í °øÁ¤ÇÑ ÀλçÀÌÆ®¸¦ ¹ÙÅÁÀ¸·Î ÇÑ ´ç»çÀÇ º¸°í¼­´Â °í°´ÀÌ ÇÊ¿ä·Î ÇÏ´Â Á¤È®¼º°ú ½Å·Ú¼ºÀ» Á¦°øÇÕ´Ï´Ù. ´Ù¸¥ °÷¿¡¼­´Â ¾òÀ» ¼ö ¾ø´Â ÀÎÅͺä¿Í µ¥ÀÌÅÍ¿¡ ´ëÇÑ µ¶Á¡Àû Á¢±Ù, Áö¼ÓÀûÀÎ ½ÃÀå ¸ð´ÏÅ͸µÀ» ÅëÇØ ½ÃÀå ¿ªÇÐÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. 40°³ ÀÌ»óÀÇ ¿ªµ¿ÀûÀÎ Áúº´ ¿µ¿ªÀ» ´Ù·ç°í ÀÖÀ¸¸ç, KOL ÀλçÀÌÆ®¿Í Á¤·®Àû ÀÇ»ç Á¶»ç¸¦ Æ÷ÇÔÇÑ ÀÇ»ç ÀÎÅÚ¸®Àü½º, ±×¸®°í ÀÇ·á ¹®Á¦, µðÁöÅÐ Çコ, ¿µ¾÷ ¹× ¸¶ÄÉÆÃ, ½ÃÀå Á¢±Ù ¹× ±âŸ ºÐ¾ßÀÇ À̽´¿¡ ´ëÇÑ ¾÷°è Àü¹®°¡µéÀÇ °ßÇØ¸¦ Á¦°øÇÏ´Â ´ç»çÀÇ º¸°í¼­´Â º¸´Ù ½º¸¶Æ®ÇÏ°í µ¥ÀÌÅÍ ±â¹ÝÀÇ ÀÇ»ç°áÁ¤À» ³»¸®°í ±Þº¯ÇÏ´Â ¾÷°è¿¡¼­ °æÀï·ÂÀ» À¯ÁöÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù.

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

This report examines the intersection of FemTech and personalised medicine, analysing how digital health innovations are reshaping the landscape of women's health. It explores the evolution of FemTech from consumer-focused applications to clinically integrated solutions, the persistent data gap in women's health research and the challenges of generating robust real-world evidence.

Gain insights into strategies for integrating digital technologies with traditional pharmaceutical treatments, the importance of inclusive clinical trial design and the critical role of partnerships between pharmaceutical companies and FemTech startups. This report also addresses the commercial and regulatory considerations necessary for advancing innovation and highlights the broader economic and societal impact of improving women's health outcomes through collaborative, data-driven approaches.

Key Questions Answered:

Key Companies:

  • Clue
  • Evinova
  • IBSA UK
  • Theramex
  • UCB
  • QVin
  • Genentech
  • K'ept Health
  • TherapeuticsMD
  • Agile
  • Eli Health
  • Noom
  • Wisp
  • Incora Health
  • Aura Fertility
  • LiGalli Health
  • Novartis
  • ImageBiopsy Lab
  • Organon
  • Boston Consulting Group

Partial List of Participating Experts:

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â